Drug Trial Radar · NCT05878769
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Jun 28, 2023
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
AstegolimabDrug
Participants will receive SC astegolimab Q2W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of all adverse events (AEs)Time frame: Up to 12 weeks after last dose of study treatment
Locations
480 sites in 40 countries. Site status is shown where the registry gives one.
UAB Lung Health Center
Birmingham, Alabama
SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS
Dothan, Alabama
Jasper Summit Research LLC
Jasper, Alabama
Pulmonary Associates of Mobile PC
Mobile, Alabama
Pulmonary Associates Deer Valley Office
Phoenix, Arizona
AES - DRS - Synexus Clinical Research US, Inc. - Tucson
Tucson, Arizona
Kern Allergy and Medical Research
Bakersfield, California
Cadena Care Institute, LLC
Poway, California
Apex Clinical Research
San Diego, California
St Francis Medical Institute ClinEdge PPDS
Clearwater, Florida
Finlay Medical Research Corporation
Greenacres City, Florida
Flourish Research - Leesburg - PPDS
Leesburg, Florida
Advanced Pulmonary Research Institute
Loxahatchee Groves, Florida
San Marcus Research Clinic Inc.
Miami, Florida
Finlay Medical Research Corporation
Miami, Florida
Oceane7 Medical & Research Center, Inc.
Miami, Florida
Research Institute of South Florida Inc
Miami, Florida
Diverse Clinical Research, LLC
Miami, Florida
Central Florida Pulmonary Group, PA
Orlando, Florida
Florida Institute for Clinical Research, LLC
Orlando, Florida
Flourish Research - Orlando - PPDS
Winter Park, Florida
Pivotal Research Solutions
Stonecrest, Georgia
Northwestern Center for Clinical Research
Chicago, Illinois
ASHA Clinical Research - ClinEdge - PPDS
Hammond, Indiana
Best Clinical Trials
New Orleans, Louisiana
Paul A. Shapero, MD, PA
Bangor, Maine
Exordia Medical Research, Inc.
Fall River, Massachusetts
Pulmonary Research Institute of Southeast Michigan
Farmington Hills, Michigan
Flushing Road Internal Medicine and Pediatrics - F
Flint, Michigan
Revive Research Institute
Southfield, Michigan
Oakland Medical Research Center
Troy, Michigan
The Lung Research Center
Chesterfield, Missouri
Hannibal Regional Healthcare System HRMG Hannibal
Hannibal, Missouri
Midwest Chest Consultants
Saint Charles, Missouri
Washington University School of Medicine in St. Louis
St Louis, Missouri
Midwest Clinical Research LLC
St Louis, Missouri
The Machuca Foundation Inc
Las Vegas, Nevada
Sierra Clinical Research - ClinEdge - PPDS
Las Vegas, Nevada
Renown Regional Medical Center Hospital
Reno, Nevada
AES - DRS - Synexus Clinical Research US, Inc. - New York
New York, New York
Showing 40 of 480 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.